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PBSCa b s t r a c t
Previous studies have shown that risks of collection-related pain and symptoms are associated with sex, body
mass index, and age in unrelated donors undergoing collection at National Marrow Donor Program centers.
We hypothesized that other important factors (race, socioeconomic status [SES], and number of procedures at
the collection center) might affect symptoms in donors. We assessed outcomes in 2726 bone marrow (BM)
and 6768 peripheral blood stem cell (PBSC) donors collected between 2004 and 2009. Pain/symptoms are
reported as maximum levels over mobilization and collection (PBSC) or within 2 days of collection (BM) and
at 1 week after collection. For PBSC donors, race and center volumes were not associated with differences in
pain/symptoms at any time. PBSC donors with high SES levels reported higher maximum symptom levels 1
week after donation (P ¼ .017). For BM donors, black males reported signiﬁcantly higher levels of pain (OR,
1.90; CI, 1.14 to 3.19; P ¼ .015). No differences were noted by SES group. BM donors from low-volume centers
reported more toxicity (OR, 2.09; CI, 1.26 to 3.46; P ¼ .006). In conclusion, race and SES have a minimal effect
on donation-associated symptoms. However, donors from centers performing  1 BM collection every 2
months have more symptoms after BM donation. Approaches should be developed by registries and low-
volume centers to address this issue.
 2015 American Society for Blood and Marrow Transplantation.INTRODUCTION Analyst 2012 dataset was used to extract median household income for each
The pattern of acute toxicities associated with bone
marrow (BM) and peripheral blood stem cell (PBSC) donation
in unrelated donors has been well described in several
studies from the National Marrow Donor Program (NMDP)
[1-3]. Several predonation demographic factors from these
and other studies have been associated with an increase in
acute toxicity, speciﬁcally age, gender, body mass index (in
PBSC but not BM donors), and anesthetic type [1-10]. It is
important to fully understand factors predictive of increased
donor risk because knowledge of their impact on post-
donation recovery helps us to tailor the predonation consent
information to the speciﬁc donor, more closely follow at-risk
donors during the recovery period, or institute interventions
to prevent symptoms in speciﬁc groups of donors.
Race/ethnicity and socioeconomic status (SES) have been
linked to pain experience and perception in several studies in
other areas of medicine such as orthopedics and chronic pain
[11-13], but thus far neither have been addressed in the
unrelated hematopoietic cell donor population. In addition,
the impact on donor outcome of the number of collections
performed annually by a center is unknown, and recom-
mendations for a minimum number of procedures per year
by regulatory bodies are often not based on data. Collection
centers vary tremendously in overall numbers of procedures
performed and experience of individuals at that center per-
forming BM collection procedures. The aim of this study was
to examine the relationship between donor race/ethnicity,
donor SES, and collection center volumes on the acute tox-
icities (up to 1 week) experienced by NMDP donors.
METHODS
Study Population
The study population consisted of ﬁrst-time volunteer US donors from
the NMDP who underwent granulocyte colony-stimulating factor (G-CSF)
(ﬁlgastrim, Neupogen; Amgen, Thousand Oaks, CA) mobilized PBSC collec-
tion or BM harvest from January 1, 2004 to July 31, 2009. Donors for whom
data were available from baseline to the ﬁrst day of apheresis on the NMDP
data collection forms were included. Donors enrolled in BMT CTN protocol
02-01 [14] and rare donors who donated BM after G-CSF administration
were excluded. Donors from centers who provided only nonresidential zip
codes (eg, work, university, or donor center zip codes) were excluded from
the SES analyses (n ¼ 534).
Donor race/ethnicity was self-reported. Donor race and ethnicity were
classiﬁed as non-Hispanic white, Hispanic-all races, non-Hispanic black,
non-Hispanic Asian/non-Hispanic Paciﬁc Islander, and non-Hispanic-other.
SES was deﬁned as the median household income in the donor’s census
block group. Each donor address was geocoded using the ArcGIS 10.1
Business Analyst US address locater (Esri, Redlands, CA). The Esri Businesscensus block group. If the census block group could not be located from
reported street address, median household income from the donor’s zip
code was used instead. Collection center and apheresis center size were
based on reaccreditation numbers using the total number of either BM
collections for calendar years 2005 to 2008 or PBSC collections for calendar
years 2004 to 2008 (regardless of whether autologous or allogeneic).
All donors included in the study provided written informed consent for
participation in Center for International Blood and Marrow Transplant
Research (CIBMTR) research studies approved by the NMDP Institutional
Review Board. This study was conducted in accordance with the Declaration
of Helsinki. Donors were evaluated for medical suitability, transplantation-
transmissible infectious diseases, and contraindications for PBSC or BM
donation using standardized NMDP criteria.
Data Collection
Data collection began at the time of the donor’s medical evaluation to
determine suitability to donate hematopoietic progenitor cells. For PBSC
donations, data collection occurred during each day of G-CSF and on the day
of each apheresis procedure. For BM donations, data collection occurred on
the day of BM collection. Both BM and PBSC donors were contacted by the
donor center 2 days after donation, 1 week after donation, and weekly
thereafter until complete recovery. “Complete recovery”was assessed by the
donor center coordinator/medical director and based on reports of return to
baseline function with no ongoing symptoms.
Because this study addressed acute toxicity, only day 2 and 1week forms
were analyzed. Detailed questions using the toxicity criteria modeled on
Common Terminology Criteria for Adverse Events (version 4; available at
http://evs.nci.nih.gov/ftp1/CTCAE/CTCAE_4.03_2010-06-14_QuickReference_
5x7.pdf) were used to assess speciﬁc symptoms, to measure the donor’s
overall health, and to capture any toxicity the donormay have experienced as
a result of the hematopoietic progenitor cells donation process. Symptoms
assessed included fever, fatigue, rash, local reactions, nausea, vomiting,
anorexia, insomnia, dizziness, syncope, pain, and infections. In addition, a
complete blood count and WBC differential were performed at the initial
medical evaluation, on the ﬁrst day of G-CSF, the day(s) of collection, and at
annual follow-ups.
PBSC Donation
All PBSC mobilizations were performed according to the NMDP-
sponsored and Institutional Review Boardeapproved research protocol for
manufacturing PBSC products, operated under an Investigational New Drug
application with the US Food and Drug Administration. G-CSF dose was
approximately 10 mg/kg/day actual body weight rounded to combinations of
300-mg and 480-mg vials, as long as protocol-deﬁned targets of 13.3 mg/kg/
day were not exceeded. Typically, donors received subcutaneous G-CSF daily
for 4 days before and on the ﬁrst day of apheresis. All donors underwent a
maximum of 2 days of apheresis. The volume of whole blood processed was
targeted to be between 12 and 24 L per collection. If the PBSC product could
not be collected using peripheral veins, a central venous catheter was used.
BM Donation
One or 2 autologous blood units were potentially collected from the
donor before donation, based on individual assessment. BM was collected
from the donor’s posterior iliac crests in an operating room under either
B.E. Shaw et al. / Biol Blood Marrow Transplant 21 (2015) 1830e18381832general or regional (spinal or epidural) anesthesia. The NMDP guidelines
recommend a duration of anesthesia of less than 150 minutes and a
maximum collection volume of 20 mL/kg.Endpoints and Statistical Analysis
The following endpoints were analyzed: incidence of grades 2 to 4 and
grades 3 to 4 skeletal pain and highest toxicity level (modiﬁed toxicity
criteria [MTC]) across selected body symptoms frequently associated with
collection (fever in the absence of signs of infection, fatigue, skin rash, local
reactions, nausea, vomiting, anorexia, insomnia, dizziness, and syncope).
Skeletal pain was deﬁned as pain in at least 1 of the following sites: back,
bone, headache, hip, limb, joint, or neck. The severity of skeletal pain was
deﬁned as the maximum grade among these pain sites. Pain/symptoms
were reported and analyzed as maximum levels over mobilization and
collection (PBSC) or within 2 days of collection (BM) and at 1 week after
collection.
Donor and collection characteristics were described using frequencies
and percentages or median and range as appropriate, separately by groups
based on center volume. Variables were compared using the Pearson chi-
square test for categorical variables and the Kruskal-Wallis test for contin-
uous variables. Incidence rates for pain and symptoms were described using
frequencies and percentages.
We examined the impact of the main effects of race, SES, and center
volume in multivariate models on 4 outcomes for each donor type: grades 2
to 4 maximum skeletal pain at day 2 (BM) or from mobilization through
collection (PBSC), grades 2 to 4 maximum skeletal pain at 1 week, grades 2
to 4 maximum MTC score at day 2 (BM) or from mobilization through
collection (PBSC), and grades 2 to 4 maximum MTC score at 1 week. Other
toxicity outcomes were generally too low in frequency for multivariate
modeling.
Generalized linear mixed models were used to ﬁt logistic regression
models to each outcome with random effects for collection center (BM) or
apheresis center (PBSC). In each case, the 3 main effects were forced into
the model, whereas other donor characteristics were added in a stepwise
manner. The optimal cutpoint based on maximum likelihood was investi-
gated for the number of BM performed and found to be 1 BM collection
every 2 months. All model results use this optimal cutpoint. All statistical
analyses were performed using SAS EG 4.3 and SAS 9.3 (SAS Institute,
Cary, NC).RESULTS
Donor Demographics
The characteristics of 2726 BM and 6768 PBSC donors are
shown in Tables 1 and 2, respectively, displayed in quartiles
reﬂecting the total activity of all centers (as deﬁned in the
methods). BM donations were facilitated by 81 donor centers
and 83 collection centers. The median number of BM col-
lections per center in this study population was 43 (range,
0 to 573). The median volume harvested was 12.70 mL/kg of
donor weight. In 4.12% of donors this exceeded the recom-
mended maximum collection volume. There were several
signiﬁcant differences between the donors based on center
volume (Table 1); however, this variationwas not distributed
in a linear fashion. For example, although the lowest and
highest volume centers had the largest proportion of non-
Hispanic whites and highest median income, the low-
volume centers had older donors and more female donors
comparedwith the highest volume centers. In addition, more
collections occurred in low-volume centers in the early years
of the study.
PBSC donations were facilitated by 76 donor centers and
98 apheresis centers. The median number of apheresis pro-
cedures per center in this study population was 520 (range,
0 to 5,953). We found that the lowest volume centers had
more non-Hispanic whites and the lowest median household
income. The lowest volume centers had the highest per-
centage of second day collections. Several differences existed
between baseline blood counts (Table 2). As in BM, more
collections occurred in low-volume centers in the early years
of the study.Multivariate Analysis
Pain and toxicity in PBSC donors
As previously shown, female (pain at day 2: odds ratio
[OR], 1.62, P < .001; and 1 week: OR, 1.53, P ¼ .048; MTC at
day 2: OR, 1.96, P < .001; and 1 week: OR, 1.67, P ¼ .014) and
obese (pain at day 2: OR,1.31, P< .001; MTC at day 2: OR,1.47,
P < .001) donors experienced more symptoms with dona-
tion. There was no impact of race/ethnicity or apheresis
center volume on any pain or toxicity outcome of PBSC do-
nors at any time. Of interest, donors in a higher income
census block reported higher maximum toxicity levels 1
week postdonation (P ¼ .025). We also found a differential
effect of age, with donors over age 40 years having lower
painwith donation comparedwith younger donors (P< .001)
but all donors over age 30 years having greater pain at 1
week (P ¼ .003). Donors aged 30 to 39 had a higher MTC
through donation compared with both younger and older
donors (P¼ .021). Finally, we found aWBC count> 7.6 109/
L at baseline to be associated with higher MTC through
donation (OR, 1.21; P ¼ .004) and at 1 week after (OR, 1.86;
P ¼ .003) and a mononuclear cell count > 2.7  109/L at
baseline to be associated with higher pain levels through
donation (OR, 1.2; P ¼ .002).
Pain and toxicity in BM donors
All statistically signiﬁcant outcomes related to pain and
maximum toxicity on day 2 and 1 week postdonation are
displayed in Tables 3 through 6. Female donors experienced
more symptoms with donation (pain at 1 week: OR, 2.07, P <
.001; MTC at day 2: OR, 2.08, P< .001; and 1week: OR, 2.28, P
< .001) and donors older than 30 years had signiﬁcantly
higher MTC at 1 week (P ¼ .020). There was no impact of SES
on any pain or toxicity outcome at any time. The only sig-
niﬁcant impact associated with race/ethnicity was a higher
incidence of grades 2 to 4 skeletal pain on day 2 after BM
collection in black males (OR, 1.91; P ¼ .014). The collection
center volume had a signiﬁcant impact on the MTC on day 2
(P ¼ .068) and 1 week (P ¼ .004) after donation (Tables 3 and
4, Figure 1). At 1 week, donors from any center performing
fewer than 24 collections reported more toxicity (OR, 2.09;
conﬁdence interval, 1.26 to 3.46; P ¼ .004) (Table 4). Finally,
we found that donors with neutrophils > 3.2  109/L at
baseline had more pain on day 2 (P ¼ .002); those who were
cytomegalovirus positive had more pain at 1 week (P ¼ .009)
and normal/underweight donors had higher MTC at day 2
(P ¼ .029).
DISCUSSION
The results of this study show that center volume was an
important factor associated with acute toxicity for BM do-
nors. In contrast, we did not ﬁnd an impact of center volumes
on recovery of PBSC donors, and race and SES had only a
minor effect on acute toxicity symptoms associated with
either PBSC or BM donation.
We were reassured to see little consistent impact of the
additional demographic factors of race and SES on donor
toxicities. Previous studies have demonstrated increased
pain in African Americans [13,15], which we noted here only
for a single outcome where black males had a signiﬁcantly
higher skeletal pain score on day 2 after BM donation (which
resolved by 1 week). The reasons for this disparity are not
clear. Likewise, the ﬁnding of a higher MTC in donors with a
higher SES at 1 week after PBSC donation was not found at
other time points. Although SES has been shown to impact
symptoms in some chronic conditions such as ﬁbromyalgia
Table 1
Characteristics of First-Time NMDP Donors Who Donated BM between January 1, 2004 and July 31, 2009 by Collection Center Size*
Variable 0-18 Collections 19-43 Collections 44-76 Collections 77-573 Collections P
Number of donors 248 548 635 1295
Number of centers 19 27 20 17
Median household income in the donor’s census
block group, 2012y,z
.059
0-25,000 4 (2) 16 (3) 25 (4) 33 (4)
25,001-50,000 74 (30) 179 (35) 231 (37) 241 (30)
50,001-100,000 118 (49) 245 (48) 274 (44) 415 (51)
>100,000 40 (16) 63 (12) 72 (12) 108 (13)
Unknown 7 (3) 11 (2) 20 (3) 16 (2)
Donor race <.001
Non-Hispanic white 213 (86) 370 (68) 440 (69) 912 (70)
Hispanic, all races 10 (4) 88 (16) 78 (12) 127 (10)
Non-Hispanic black 11 (4) 40 (7) 32 (5) 82 (6)
Non-Hispanic Asian/non-Hispanic Paciﬁc Islander 7 (3) 23 (4) 46 (7) 68 (5)
Non-Hispanic other, unknown 7 (3) 27 (5) 39 (6) 106 (8)
Donor-related
Donor age at donation <.001
18-29 72 (29) 143 (26) 206 (32) 466 (36)
30-39 78 (31) 209 (38) 186 (29) 407 (31)
40-49 68 (27) 151 (28) 171 (27) 329 (25)
50þ 30 (12) 45 (8) 72 (11) 93 (7)
Median (range) 37 (19-60) 36 (19-61) 36 (19-61) 34 (19-61) .007
Donor sex <.001
Female 105 (42) 243 (44) 299 (47) 441 (34)
Male 143 (58) 305 (56) 336 (53) 854 (66)
Donor BMI, kg/m2 .166
Underweight: <18.5 1 (<1) 4 (1) 5 (1) 4 (<1)
Normal: 18.5-24.9 71 (29) 187 (34) 193 (30) 374 (29)
Overweight: 25-29.9 102 (41) 197 (36) 223 (35) 522 (40)
Obese: 30þ 74 (30) 160 (29) 214 (34) 395 (31)
Median (range) 27.5 (18.2-42.1) 27.0 (17.6-45.6) 27.7 (16.1-50.9) 27.4 (17.8-48.5) .314
Baseline WBC, 109/L
No. evaluated 248 548 635 1295
Median (range) 6.3 (2.9-12.3) 6.3 (2.3-14.2) 6.5 (3.1-12.9) 6.4 (3.0-14.2) .077
Baseline platelets, 109/L
No. evaluated 248 548 634 1295
Median (range) 259 (138-419) 254 (139-490) 256 (130-465) 252 (104-534) .374
Baseline hemoglobin, g/dL
No. evaluated 248 548 635 1295
Median (range) 14.6 (10.7-18.3) 14.6 (8.6-17.9) 14.7 (10.4-17.6) 14.7 (9.2-19.0) .129
Baseline neutrophils, 109/L
No. evaluated 247 548 635 1295
Median (range) 4.1 (1.5-9.9) 4.0 (1.0-12.5) 4.1 (1.6-9.9) 4.0 (1.2-10.3) .052
Baseline mononuclear cells, 109/L
No. evaluated 248 548 632 1289
Median (range) 2.2 (1.2-5.3) 2.3 (.9-5.2) 2.3 (.9-5.0) 2.3 (.9-7.2) .473
Donor CMV .065
Negative 161 (65) 305 (56) 348 (55) 738 (57)
Positive 86 (35) 243 (44) 287 (45) 555 (43)
Unknown/inconclusive 1 (<1) 0 0 2 (<1)
Collection-related
Year of donation <.001
2004 88 (35) 100 (18) 112 (18) 191 (15)
2005 61 (25) 93 (17) 93 (15) 202 (16)
2006 36 (15) 97 (18) 124 (20) 222 (17)
2007 24 (10) 95 (17) 114 (18) 238 (18)
2008 21 (8) 106 (19) 113 (18) 297 (23)
2009 18 (7) 57 (10) 79 (12) 145 (11)
Type of anesthesia <.001
Epidural 2 (1) 3 (1) 4 (1) 22 (2)
General 229 (92) 533 (97) 608 (96) 1249 (97)
Local 0 0 1 (<1) 0
Spinal 17 (7) 12 (2) 22 (3) 23 (2)
Unknown 0 N/A 0 N/A 0 N/A 1 N/A
BMI indicates body mass index; CMV, cytomegalovirus.
Values in parentheses are percents, unless otherwise noted.
* Collection center size based on NMDP reaccreditation numbers: uses total number of bonemarrow collections, regardless of donor source, for calendar years
2005-2008.
y Donors from the centers who provided only nonresidential zip codes (eg, work, university, or donor center zip codes) were excluded from the SES analyses.
z If the census block group could not be located from reported street address, median household income from donor’s zip code was used instead.
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Number of donors 543 1674 2845 1686 20
Number of centers 22 24 24 22 6
Median household income in the
donor’s census block group, 2012y,z
<.001
0-25,000 27 (5) 37 (2) 75 (4) 43 (3) 0
25,001-50,000 184 (34) 475 (30) 512 (30) 473 (31) 4 (57)
50,001-100,000 251 (47) 813 (51) 827 (49) 713 (46) 2 (29)
>100,000 56 (10) 205 (13) 252 (15) 276 (18) 0
Unknown 19 (4) 55 (3) 34 (2) 32 (2) 1 (14)
Donor race <.001
Non-Hispanic white 458 (84) 1168 (70) 2183 (77) 1258 (75) 16 (80)
Hispanic, all races 26 (5) 202 (12) 241 (8) 139 (8) 1 (5)
Non-Hispanic black 13 (2) 72 (4) 148 (5) 87 (5) 0
Non-Hispanic Asian/non-Hispanic
Paciﬁc Islander
17 (3) 117 (7) 58 (2) 102 (6) 0
Non-Hispanic other, unknown 29 (5) 115 (7) 215 (8) 100 (6) 3 (15)
Donor-related
Donor age at donation <.001
18-29 141 (26) 509 (30) 995 (35) 521 (31) 7 (35)
30-39 185 (34) 531 (32) 935 (33) 550 (33) 6 (30)
40-49 158 (29) 431 (26) 672 (24) 430 (26) 3 (15)
50þ 59 (11) 203 (12) 243 (9) 185 (11) 4 (20)
Median (range) 37 (19-60) 36 (18-60) 35 (19-61) 36 (19-61) 35 (20-61) <.001
Donor sex <.001
Female 230 (42) 746 (45) 908 (32) 706 (42) 8 (40)
Male 313 (58) 928 (55) 1937 (68) 980 (58) 12 (60)
Donor BMI, kg/m2 .085
Underweight: <18.5 2 (<1) 9 (1) 17 (1) 13 (1) 0
Normal: 18.5-24.9 146 (27) 504 (30) 795 (28) 521 (31) 4 (20)
Overweight: 25-29.9 202 (37) 641 (38) 1183 (42) 625 (37) 8 (40)
Obese: 30þ 193 (36) 520 (31) 849 (30) 527 (31) 8 (40)
Unknown 0 N/A 0 N/A 1 N/A 0 N/A 0 N/A
Median (range) 28.0 (18.0-49.7) 27.4 (16.2-49.1) 27.4 (16.7-51.8) 27.4 (16.9-56.2) 27.7 (19.5-39.6) .082
Baseline WBC, 109/L
No. evaluated 543 1674 2845 1686 20
Median (range) 6.4 (3.2-14.0) 6.3 (2.9-15.6) 6.3 (2.4-16.0) 6.4 (2.3-14.5) 6.6 (4.5-11.0) .683
Baseline platelets, 109/L
No. evaluated 543 1673 2844 1686 20
Median (range) 252 (122-474) 257 (127-474) 251 (100-548) 257 (112-494) 242 (170-397) .002
Baseline hemoglobin, g/dL
No. evaluated 543 1674 2845 1686 20
Median (range) 14.7 (10.5-17.9) 14.5 (9.6-18.3) 14.9 (9.4-18.6) 14.6 (9.6-19.0) 14.6 (12.5-16.5) <.001
Baseline neutrophils, 109/L
No. evaluated 543 1673 2844 1686 20
Median (range) 4.1 (1.3-10.9) 3.9 (1.2-12.9) 3.9 (1.0-12.8) 4.0 (1.3-11.8) 3.8 (2.4-6.1) .152
Baseline mononuclear cells, 109/L
No. evaluated 538 1672 2836 1681 20
Median (range) 2.3 (1.1-4.9) 2.3 (.7-7.3) 2.3 (.8-5.9) 2.3 (.3-5.0) 2.5 (1.4-5.0) .100
Donor CMV <.001
Unknown/inconclusive 0 4 (<1) 3 (<1) 3 (<1) 0
Negative 329 (61) 937 (56) 1790 (63) 1046 (62) 15 (75)
Positive 214 (39) 733 (44) 1052 (37) 637 (38) 5 (25)
Year of donation <.001
2004 107 (20) 169 (10) 356 (13) 176 (10) 6 (30)
2005 111 (20) 258 (15) 426 (15) 303 (18) 4 (20)
2006 90 (17) 294 (18) 504 (18) 299 (18) 1 (5)
2007 79 (15) 331 (20) 574 (20) 307 (18) 6 (30)
2008 88 (16) 393 (23) 648 (23) 367 (22) 1 (5)
2009 68 (13) 229 (14) 337 (12) 234 (14) 2 (10)
Two-day collection <.001
No 290 (53) 1288 (77) 2293 (81) 1058 (63) 15 (75)
Yes 253 (47) 386 (23) 552 (19) 628 (37) 5 (25)
Precollection WBC, 109/L .431
No. evaluated 543 1674 2845 1685 20
Median (range) 37.5 (9.6-98.9) 38.3 (11.3-93.4) 38.9 (11.2-117) 38.9 (10.6-89.7) 37.6 (18.9-64.3)
CD34þ at collection, 106 <.001
No. evaluated 409 1508 2430 1480 18
Median (range) 636.0 (7.1-3486.2) 611.4 (.9-4013.6) 743.6 (2.8-5967.0) 657.2 (.7-13428.1) 592.2 (77.8-1262.7)
(Continued on next page)












Day 1 G-CSF dose per donor weight, mg/kg .021
No. evaluated 543 1674 2836 1685 20
Median (range) 10.5 (5.3-14.6) 10.6 (7.1-14.5) 10.6 (2.5-15.7) 10.6 (4.5-17.7) 10.5 (9.0-12.8)
Total G-CSF dose per donor weight, mg/kg <.001
No. evaluated 543 1674 2842 1686 20
Median (range) 52.3 (35.0-73.2) 52.9 (31.2-70.6) 52.7 (5.2-74.4) 52.7 (21.2-71.4) 52.3 (35.9-63.9)
Values in parentheses are percents, unless otherwise noted.
* Apheresis center size based on reaccreditation numbers; uses total number of autologous, related and unrelated allogeneic PBSC collections for calendar
years 2004-2008.
y Donors from the centers who provided only nonresidential zip codes (eg, work, university or donor center zip codes) were excluded from the SES analyses.
z If the census block group could not be located from reported street address, median household income from donor’s zip code was used instead.
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groups who have more troublesome symptoms. Interest-
ingly, 1 study showed that analgesia use is lower in those
with a higher SES after a medical procedure [18], an outcome
we did not examine in our study. Because SES assignment
was based only on the census block group the donor lived in
at the time of donation, it is possible that we did not have
enough information to properly understand this outcome.
Education level and occupation were not considered in this
study.
To date, a comprehensive study investigating the toxicity
outcomes of donors has not looked at the variable of center
size and experience, and our ﬁndings with regards to BM
donors are of great interest and require further investigation.
Although a few studies have investigated a center effect or
donor demographic factors on the quality of BM harvested
[19-21], none of these has reported on the donor’s outcome.
This issue is of critical importance to the NMDP and other
donor registries not only to ensure the best donor experience
but also to assist in accreditation of centers. This ﬁnding mayTable 3
Multivariate Analysis of Grades 2-4 MaximumMTC Grade at Day 2 after BM
Donation
Variable n OR Lower Upper P





25,001-50,000 721 1.01 .51 2.00 .985
50,001-100,000 1050 .97 .49 1.92 .927
>100,000 281 .93 .44 1.95 .839
Donor race .821
Non-Hispanic white 1920 1.00
Hispanic, all races 302 .81 .54 1.20 .294
Non-Hispanic black 165 .98 .62 1.56 .937
Non-Hispanic Asian/non-
Hispanic Paciﬁc Islander
144 1.14 .69 1.88 .599
Non-Hispanic other, unknown 178 .99 .63 1.56 .974
Collection center size .068
24 (1 every 2 months) 2138 1.00
<24 (<1 every 2 months) 265 1.55 .97 2.47 .068
Sex <.001
Male 1627 1.00
Female 1082 2.08 1.66 2.62 <.001
Donor BMI, kg/m2 .029
Normal/underweight: <24.9 835 1.00
Overweight: 25-29.9 1036 .76 .59 .99 .041
Obese: 30þ 838 .70 .53 .93 .013
* Donors from the centers who provided only nonresidential zip codes
(eg, work, university, or donor center zip codes) were excluded from the SES
analyses.
y If the census block group could not be located from reported street
address, median household income from donor’s zip code was used instead.represent a predictable result of less experience at a given
center, warranting special attention and intervention to
ensure appropriate outcomes for BM donors harvested at
small centers.
The number of BM harvests performed in unrelated do-
nors annually has reduced dramatically over the last decade,
although there is some evidence of a plateau in recent years.
Currently, 20% of unrelated donor transplants reported to the
CIBMTR are performed using BM [22]. The percentage of
donors undergoing BM harvest versus PBSC is even lower in
(adult) related donors, with the overall effect a lack of
exposure to this procedure for many hematologists/BMT
specialists and other BM harvest team members. A recently
published study by Remberger et al. [23] reported a signiﬁ-
cant reduction in the number of CD34 cells harvested from
BM in a more contemporary time period (2010 to 2011)
compared with an earlier time period (1995 to 1997). In
addition, a single-center study has shown a marked down-
ward trend in total nucleated cell numbers harvested fromTable 4
Multivariate Analysis of Grades 2-4 Maximum MTC Grade at 1 Week after
BM Donation
Variable n OR Lower Upper P





25,001-50,000 648 .51 .20 1.30 .159
50,001-100,000 956 .66 .26 1.66 .380
>100,000 254 .60 .22 1.68 .331
Donor race .813
Non-Hispanic white 1720 1.00
Hispanic, all races 272 .87 .49 1.55 .634
Non-Hispanic black 137 .71 .33 1.53 .383
Non-Hispanic Asian/non-Hispanic
Paciﬁc Islander
121 .68 .28 1.66 .395
Non-Hispanic other, unknown 153 .86 .41 1.77 .675
Collection center size .004
24 (1 every 2 months) 2138 1.00
<24 (<1 every 2 months) 265 2.09 1.26 3.46 .004
Sex <.001
Male 1432 1.00
Female 971 2.28 1.62 3.22 <.001
Age at donation .020
18-29 767 1.00
30-39 783 1.62 1.02 2.56 .040
40-49 633 2.05 1.29 3.25 .002
50þ 220 1.91 1.03 3.54 .040
* Donors from the centers who provided only nonresidential zip codes
(eg, work, university, or donor center zip codes) were excluded from the SES
analyses.
y If the census block group could not be located from reported street
address, median household income from donor’s zip code was used instead.
Table 5
Multivariate Analysis of Grades 2-4 Maximum Skeletal Pain on Day 2 after
BM Donation
Variable n OR Lower Upper P
Donor race .001
Male .008
Non-Hispanic white 1220 1.00
Hispanic, all races 146 .75 .48 1.18 .213
Non-Hispanic black 71 1.91 1.14 3.20 .014
Non-Hispanic Asian/non-Hispanic
Paciﬁc Islander
86 .61 .34 1.10 .100
Non-Hispanic other, unknown 106 .63 .37 1.08 .094
Female .136
Non-Hispanic white 702 1.00
Hispanic, all races 156 .81 .54 1.23 .323
Non-Hispanic black 94 .57 .34 .95 .030
Non-Hispanic Asian/non-Hispanic
Paciﬁc Islander
58 1.04 .57 1.92 .892
Non-Hispanic other, unknown 72 1.29 .77 2.18 .333
Median household income in the
donor’s census block group, 2012*,y
.689
0-25,000 78 1.00
25,001-50,000 722 .68 .40 1.16 .160
50,001-100,000 1051 .69 .41 1.16 .160
>100,000 281 .66 .37 1.17 .154
Collection center size .338
24 (1 every 2 months) 2138 1.00
<24 (<1 every 2 months) 265 1.25 .79 1.95 .338
Neutrophils at baseline, 109/L
<3.2 650 1.00
3.2 2061 1.38 1.13 1.70 .002
* Donors from the centers who provided only nonresidential zip codes
(eg, work, university, or donor center zip codes) were excluded from the SES
analyses.
y If the census block group could not be located from reported street
address, median household income from donor’s zip code was used instead.
Figure 1. Highest toxicity level of key symptoms (fever in the absence of signs
of infection, fatigue, skin rash, local reactions, nausea, vomiting, anorexia,
insomnia, dizziness, and syncope) for BM donors by collection center volume:
at baseline, during the pericollection period, and postdonation.
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tion, April 27, 2015). Authors of both studies speculate that
these effects are due to a reduction in operator expertise.
Indeed, 1 study that assessed the impact of a new BM needleTable 6
Multivariate Analysis of Grades 2-4 Maximum Skeletal Pain at 1 Week after
BM Donation
Variable n OR Lower Upper P
Median household income in the
donor’s census block group, 2012*,y
.114
0-25,000 70 1.00
25,001-50,000 648 .83 .38 1.82 .649
50,001-100,000 958 1.11 .51 2.39 .790
>100,000 254 .59 .24 1.44 .248
Donor race .479
Non-Hispanic white 1720 1.00
Hispanic, all races 273 .78 .49 1.23 .280
Non-Hispanic black 137 1.25 .76 2.07 .383
Non-Hispanic Asian/non-Hispanic
Paciﬁc Islander
121 .72 .36 1.43 .352
Non-Hispanic other, unknown 153 .82 .47 1.42 .479
Collection center size .164
24 (1 every 2 months) 2138 1.00
<24 (<1 every 2 months) 265 1.41 .87 2.28 .164
Sex <.001
Male 1432 1.00
Female 972 2.07 1.59 2.70 <.001
Donor CMV .009
Negative 1363 1.00
Positive 1041 1.43 1.09 1.87 .009
* Donors from the centers who provided only nonresidential zip codes
(eg, work, university, or donor center zip codes) were excluded from the SES
analyses.
y If the census block group could not be located from reported street
address, median household income from donor’s zip code was used instead.on harvest quality [24] reported a “learning effect” for the
same operators performing more harvest over time, because
larger collection volumes were consistently obtained in the
later time period.
These diminishing numbers of BM collections have led
the Foundation for the Accreditation of Cellular Therapy
standards committee to lower the minimum number of BM
harvests required by a facility to be accredited, as follows: A
minimum of 1 marrow collection procedure shall have been
performed in the 12-month period immediately preceding
facility accreditation, and a minimum average of 1 marrow
collection procedure per year shall be performed within the
accreditation cycle [25]. In this study we deﬁned center size
by the total number of collections performed (related and
unrelated) and found that in those centers performing  1
BM collection every 2 months over a 3- to 4-year period,
donors had a longer time to recovery. This is well above the
current minimum standard required by the Foundation for
the Accreditation of Cellular Therapy for center accredita-
tion and suggests that the standard should be revised or
that other measures should be taken to address this issue.
Given the results of this study and the trends in BM har-
vesting volumes, we may not only see an increase in donor
acute toxicities but also a reduction in the quality of the
harvest if practice is not changed. We were not able to
accurately assess the number of BM harvests performed by
individual practitioners at collection centers. However,
we believe the harvesting process is a composite one
requiring expertise not only of the harvesting practitioner
but also the ancillary operating room staff and
anesthesiologists.
Interestingly, the effects on BM donors weremost marked
at 1 week postdonation for MTC, with little or no effect for
skeletal pain. It is thus possible that the increased symptoms
are not only related to collection variables but also to other
factors. Thismay include factors not directly addressed in this
study, such as hospitalization, advice on activities, use of and
prescriptions for analgesia and iron supplementation, and
infusion of autologous blood units [26,27]. Practice at NMDP
centers is generally to collect 1 ormore autologousunit before
donation, but in many cases these units are not returned. It is
unclear how this variable may impact the donor experience,
but this may warrant further analysis. We also did not
consider aspects of anesthesia (duration/method) in this
study because this is extremely standardized at NMDP
B.E. Shaw et al. / Biol Blood Marrow Transplant 21 (2015) 1830e1838 1837centers, following earlier studies showing the important
impact of this variable on toxicities [3]. This study was only
focused on short-term toxicities and pain and was not
designed to examine long-term donor outcomes.
Several possible strategies to address the problems
associated with collecting less BM could be proposed. First,
knowledge of this issue by centers might lead to training
and standardization of practices within centers to address
this concern. If such interventions did not lead to im-
provements in low-volume centers, a possible solution is to
consolidate collections into fewer facilities. This would be
relatively easy to achieve for registries looking after unre-
lated donors but would be a challenge for centers per-
forming related donor collections. In some countries,
registries have taken on the collection of BM from related
donors for the transplant centers. Concerning the issue of
lower total nucleated cell numbers over time, the CIBMTR is
undertaking a large study to explore this issue in more
detail [28].
In conclusion, despite a reassuring lack of major impact of
race and SES on acute toxicities in unrelated donors, we
found an increase in toxicities in BM donors who donated at
small-volume BM harvesting centers. We speculate that this
is part of a worrying trend toward reduction in the experi-
ence of BM operators, which impacts both the donor (as we
have shown) and the quality of the harvest, with obvious
detriments to the patient. A global effort is required to
address these issues.ACKNOWLEDGMENTS
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